SCHEMBL266429

SCHEMBL266429

COc1cc(OC)cc(C(=O)Nc2ccc(O)cc2C(=O)N/N=C/c2cccc(F)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.52
MAPT P10636 4/20 0.52
HPGD P15428 4/20 0.52
KMT2A Q03164 4/20 0.52
KDM4E B2RXH2 3/20 0.52
PKM P14618 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
MEN1 O00255 2/20 0.52
ALOX12 P18054 1/20 0.52
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
ALDH1A1 P00352 3/20 0.50
LMNA P02545 1/20 0.50
CTDSP1 Q9GZU7 2/20 0.49
TDP1 Q9NUW8 1/20 0.48
SLC34A2 O95436 1/20 0.48
SLC34A1 Q06495 1/20 0.48
SLC34A3 Q8N130 1/20 0.48
SLC20A1 Q8WUM9 1/20 0.48
SPHK2 Q9NRA0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266430 1.00 SMN1; SMN2 (0.52) SMN1; SMN2MAPTHPGDKMT2AKDM4E
SCHEMBL268338 0.91 HPGD (0.49) SMN1; SMN2MAPTHPGDKMT2AKDM4E
SCHEMBL268337 0.91 HPGD (0.49) SMN1; SMN2MAPTHPGDKMT2AKDM4E
SCHEMBL267637 0.90 MAPT (0.60) SMN1; SMN2MAPTHPGDKMT2AKDM4E
SCHEMBL267638 0.90 MAPT (0.60) SMN1; SMN2MAPTHPGDKMT2AKDM4E
SCHEMBL267148 0.85 KDM4E (0.66) SMN1; SMN2MAPTHPGDKMT2AKDM4E
SCHEMBL267147 0.85 KDM4E (0.66) SMN1; SMN2MAPTHPGDKMT2AKDM4E
SCHEMBL267955 0.84 NPC1 (0.59) SMN1; SMN2MAPTHPGDKMT2AKDM4E
SCHEMBL267956 0.84 NPC1 (0.59) SMN1; SMN2MAPTHPGDKMT2AKDM4E
SCHEMBL273434 0.83 NPC1 (0.53) SMN1; SMN2MAPTHPGDKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SMN1; SMN2 3975/4885MAPT 4195/4885HPGD 2509/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SMN1; SMN2 4253/4885MAPT 4648/4885HPGD 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.